Trimodality or Mulitmodality Therapy
Implementation of Hyperthermic Intrathoracic Chemotherapy (HITHOC) in Germany
Zentralblatt fur Chirurgie 2018 March 12 [Epub ahead of print] [Link] Ried M, Hofmann HS, Dienemann H, Eichhorn M Abstract INTRODUCTION: For several years, hyperthermic intrathoracic chemotherapy (HITHOC) has been performed in a few departments for thoracic surgery in a multimodality treatment regime in addition to surgical cytoreduction. Specific data about HITHOC in Germany are…
Read More18F-FDG PET/CT in the management of patients with malignant pleural mesothelioma being considered for multimodality therapy: experience of a tertiary referral center
The British Journal of Radiology 2018 March [Epub ahead of print] [Link] H St. AE et.al. Abstract OBJECTIVE: To compare the N and M staging accuracy of positron emission tomography (PET) versus CT, as per the American Joint Committee on Cancer (AJCC) 8th edition in patients with malignant pleural mesothelioma (MPM) being considered for multimodality…
Read MoreAnti-tumor immunotherapy in malignant pleural mesothelioma
Rev Mal Respir 2018 February 4 [Epub ahead of print] [Link] Scherpereel A, Willemin MC, Wasielewski E, Dhalluin X Abstract INTRODUCTION: Malignant pleural mesothelioma (MPM) is a quite rare cancer, but with increasing incidence, that is usually induced by previous asbestos exposure. Its prognosis is poor and there is no validated curative therapy to date.…
Read MoreSingle-institution experience of intensity-modulated radiotherapy for malignant pleural mesothelioma at University of Catania
Future Oncology 2018 February 5 [Link] Spatola C et. al. Abstract The multimodal approach to malignant pleural mesothelioma is gradually becoming the standard of care for this disease in patients with good performance status. Materials & methods: We report our experience concerning eight cases treated with the use of static step-and-shoot intensity-modulated radiotherapy to the…
Read MoreTreatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline
Journal of Clinical Oncology 2018 January [Epub ahead of print] [Link] Kindler HL et. al. Abstract Purpose To provide evidence-based recommendations to practicing physicians and others on the management of malignant pleural mesothelioma. Methods ASCO convened an Expert Panel of medical oncology, thoracic surgery, radiation oncology, pulmonary, pathology, imaging, and advocacy experts to conduct a…
Read MoreRadical multimodality therapy for malignant pleural mesothelioma
The Cochrane Database of Systematic Reviews 2018 January 8 [Epub ahead of print] [Link] Abdel-Rahman O, Elsayed Z, Mohamed H, Eltobgy M Abstract BACKGROUND: Malignant pleural mesothelioma is an almost always fatal tumour, for which palliative platinum-based chemotherapy is currently the standard treatment. Multimodal therapeutic strategies incorporating surgery, radiation therapy or photodynamic therapy and chemotherapy…
Read MorePredictors of trimodality therapy and trends in therapy for malignant pleural mesothelioma
European Journal of Cardio-Thoracic Surgery 2017 December [Epub ahead of print] [Link] Nelson DB et. al Abstract OBJECTIVES: Malignant pleural mesothelioma is an aggressive and rare malignancy that frequently recurs despite aggressive therapy. We evaluated the frequency of treatment with surgery, radiation or chemotherapy, changes in therapy and survival over time and factors associated with…
Read MoreNational Trends in the Epidemiology of Malignant Pleural Mesothelioma: A National Cancer Data Base Study
The Annals of Thoracic Surgery 2017 December [Epub ahead of print] [Link] Saddoughi SA, Abdelsattar ZM, Blackmon SH Abstract BACKGROUND: Malignant pleural mesothelioma (MPM) remains an aggressive malignancy that is difficult to cure. However, the treatment paradigm of MPM has evolved, and the national practice patterns are unknown. This study examined the national trends in…
Read MoreNew Concepts in the Treatment of Malignant Pleural Mesothelioma
Annual Review of Medicine 2017 October [Epub ahead of print] [Link] Wald O, Sugarbaker DJ Abstract Malignant pleural mesothelioma (MPM) is a highly aggressive and generally incurable cancer. Current anti-MPM chemotherapy-based treatments are only marginally effective, and long-term survival remains an unmet goal. Nonetheless, in selected cases, personalized surgery-based multimodality treatments (MMT) have been shown…
Read MoreA Randomized Phase II Trial of Adjuvant Galinpepimut-S, WT-1 Analog Peptide Vaccine, after Multimodality Therapy for Patients with Malignant Pleural Mesothelioma
Clinical Cancer Research 2017 September [Epub ahead of print][Link] Zauderer MG, et.al. Abstract PURPOSE: Determine the 1-year progression-free survival (PFS) among patients with malignant pleural mesothelioma (MPM) receiving the WT1 peptide vaccine galinpepimut-S after multimodality therapy vs those receiving control adjuvants. PATIENTS AND METHODS: This double-blind, controlled, two center phase II trial randomized MPM patients…
Read More